| Trial of anifrolumab in active systemic lupus erythematosus EF Morand, R Furie, Y Tanaka, IN Bruce, AD Askanase, C Richez, ... New England Journal of Medicine 382 (3), 211-221, 2020 | 982 | 2020 |
| Treat-to-target in systemic lupus erythematosus: recommendations from an international task force RF Van Vollenhoven, M Mosca, G Bertsias, D Isenberg, A Kuhn, ... Annals of the rheumatic diseases 73 (6), 958-967, 2014 | 818 | 2014 |
| Definition and initial validation of a lupus low disease activity state (LLDAS) K Franklyn, CS Lau, SV Navarra, W Louthrenoo, A Lateef, L Hamijoyo, ... Annals of the rheumatic diseases 75 (9), 1615-1621, 2016 | 614 | 2016 |
| Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosus J He, X Zhang, Y Wei, X Sun, Y Chen, J Deng, Y Jin, Y Gan, X Hu, R Jia, ... Nature medicine 22 (9), 991-993, 2016 | 523 | 2016 |
| MIF: a new cytokine link between rheumatoid arthritis and atherosclerosis EF Morand, M Leech, J Bernhagen Nature reviews Drug discovery 5 (5), 399-411, 2006 | 470 | 2006 |
| The BAFF/APRIL system in SLE pathogenesis FB Vincent, EF Morand, P Schneider, F Mackay Nature Reviews Rheumatology 10 (6), 365-373, 2014 | 448 | 2014 |
| Macrophage migration inhibitory factor in rheumatoid arthritis: evidence of proinflammatory function and regulation by glucocorticoids M Leech, C Metz, P Hall, P Hutchinson, K Gianis, M Smith, H Weedon, ... Arthritis & Rheumatism: Official Journal of the American College of …, 1999 | 444 | 1999 |
| Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective FB Vincent, EF Morand, K Murphy, F Mackay, X Mariette, C Marcelli Annals of the rheumatic diseases 72 (2), 165-178, 2013 | 442 | 2013 |
| A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS) R Van Vollenhoven, A Voskuyl, G Bertsias, C Aranow, M Aringer, ... Annals of the rheumatic diseases 76 (3), 554-561, 2017 | 380 | 2017 |
| Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial RA Furie, EF Morand, IN Bruce, S Manzi, KC Kalunian, EM Vital, TL Ford, ... The Lancet Rheumatology 1 (4), e208-e219, 2019 | 366 | 2019 |
| Macrophage migration inhibitory factor induces macrophage recruitment via CC chemokine ligand 2 JL Gregory, EF Morand, SJ McKeown, JA Ralph, P Hall, YH Yang, ... The Journal of Immunology 177 (11), 8072-8079, 2006 | 237 | 2006 |
| Role of macrophage migration inhibitory factor (MIF) in murine antigen-induced arthritis: interaction with glucocorticoids L Santos, P Hall, C Metz, R Bucala, EF Morand Clinical & Experimental Immunology 123 (2), 309-314, 2001 | 229 | 2001 |
| Stress–glucocorticoid–TSC22D3 axis compromises therapy-induced antitumor immunity H Yang, L Xia, J Chen, S Zhang, V Martin, Q Li, S Lin, J Chen, J Calmette, ... Nature medicine 25 (9), 1428-1441, 2019 | 225 | 2019 |
| Involvement of macrophage migration inhibitory factor in the evolution of rat adjuvant arthritis M Leech, C Metz, L Santos, T Peng, SR Holdsworth, R Bucala, EF Morand Arthritis & Rheumatism: Official Journal of the American College of …, 1998 | 225 | 1998 |
| A miR-19 regulon that controls NF-κB signaling MP Gantier, HJ Stunden, CE McCoy, MA Behlke, D Wang, ... Nucleic acids research 40 (16), 8048-8058, 2012 | 210 | 2012 |
| Macrophage migration inhibitory factor in systemic lupus erythematosus. A Foote, EM Briganti, Y Kipen, L Santos, M Leech, EF Morand The Journal of rheumatology 31 (2), 268-273, 2004 | 201 | 2004 |
| Modulation of inflammation and response to dexamethasone by Annexin 1 in antigen‐induced arthritis YH Yang, EF Morand, SJ Getting, M Paul‐Clark, DL Liu, S Yona, ... Arthritis & Rheumatism 50 (3), 976-984, 2004 | 198 | 2004 |
| Regulation of synoviocyte phospholipase A2 and cyclooxygenase 2 by macrophage migration inhibitory factor AV Sampey, PH Hall, RA Mitchell, CN Metz, EF Morand Arthritis & Rheumatism: Official Journal of the American College of …, 2001 | 182 | 2001 |
| 2021 DORIS definition of remission in SLE: final recommendations from an international task force RF van Vollenhoven, G Bertsias, A Doria, D Isenberg, E Morand, MA Petri, ... Lupus science & medicine 8 (1), e000538, 2021 | 176 | 2021 |
| Macrophage migration inhibitory factor in rheumatoid arthritis: clinical correlations EF Morand, M Leech, H Weedon, C Metz, R Bucala, MD Smith Rheumatology 41 (5), 558-562, 2002 | 168 | 2002 |
Alberta HoiAssociate Professor, Monash University在 monash.edu 的电子邮件经过验证
